Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
Go back to Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 226.79 +2.13 (0.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $224.66 | 52 Week High | $160.00 | |||
| Open | $226.16 | 52 Week Low | $95.80 | |||
| Day High | $227.86 | P/E | 42.15 | |||
| Day Low | $224.27 | EPS | $5.38 | |||
| Volume | 242,949 | |||||
